What Can You Expect in 2026?
Molecular glues are transforming drug discovery, unlocking novel targets once believed to be undruggable. With the market cap projected to soar from $2.1B in 2023 to $5.6B by 2030, momentum is building fast with clinical successes and landmark deals - in 2025 alone, Magnet Bio struck a $1.2 billion deal with Eli Lilly, Kymera Therapeutics and Gilead Sciences entered a $750 million partnership, and Orionis Biosciences announced a $105 million collaboration with Genentech! Yet discovery remains the key bottleneck. The 4th Molecular Glue Drug Development Summit will equip you with the cutting-edge strategies, tools, and insights needed to design, discover, and advance the next generation of molecular glues into the clinic.Â
Unmissable Event Highlights
Unlock Molecular Glues for Non-Oncology Targets
Examine how molecular glues are driving breakthroughs in neurodegeneration and autoimmune disease. From dual-action modulators and lysosomal degradation strategies to novel scaffolds with improved potency and efficacy, see how these approaches open new therapeutic frontiers outside of cancer. Â
With Expert Insights From:Â
- Dong Seok Kim, Chief Executive Officer, AevisBioÂ
- Chunhai Charlie Hao, Co-Founder, Degrome TherapeuticsÂ
- Wu Du, Senior Vice President, Medicinal Chemistry, Hinova Therapeutics
Drive Molecular Glue Innovation with Novel E3 Ligases
Harness novel ligases to unlock new targets, expand discovery strategies, and accelerate translation. Explore structural insights, diverse screening approaches, and emerging case studies that demonstrate how novel ligase–glue pairs can overcome resistance pathways and open new therapeutic opportunities.Â
With Expert Insights From:Â Â Â
- Anita Bellail, Chief Executive Officer, HB Therapeutics Â
- Stephen Hinshaw, Senior Scientist, Stanford University Â
- Dalia Barsyte-Lovejoy, Structural Genomics Consortium Â
Expand Therapeutic Opportunities with Non-Degrading Molecular Glue
Drive molecular glue innovation with cutting-edge screening and AI-driven platforms. From positive-selection systems to biology-first discovery, these approaches expand ligase diversity, reveal cooperative activity without structural data, and accelerate translation into new therapeutic opportunities across oncology, neurodegeneration, and beyond.Â
With Expert Insights From:Â Â Â
- Goutham Narla, Chief Scientific Officer, Rappta TherapeuticsÂ
- Rick Ewing, Vice President & Head of Chemistry, Rapafusyn Pharmaceuticals
- Mikolaj Slabicki, Principal Investigator, Massachusetts General Hospital Â
Propel Molecular Glue Discovery with Novel Assays & Technologies
Advance the next wave of molecular glue discovery with cutting-edge platforms that bypass structural limitations, harness synthetic positive-selection systems, and leverage library screening to reveal cooperative activity with reduced off-target risks. See how AI-driven design, predictive platforms, and biology-first strategies expand ligase diversity, accelerate translation, and open therapeutic opportunities across oncology, neurodegeneration, and beyond.Â
With Expert Insights From:Â Â
- Patrick Arsenault, Senior Director, Triana Biomedicines Â
- John McGee, Senior Vice President of Technology Platform, Parabalis Medicines Â
- Chris Tame, Chief Executive Officer, Ternary Therapeutics Â
Explore the Full Event Guide
- 20+ Leading Molecular Glue Experts Presenting
- 3 Days of Data-Driven Glues Content
- Exclusive Networking & Partnership Opportunities
- 2 Interactive & Deep-Diving Workshops
- The Definitive Meeting for Molecular Glue Drug Discovery & Development
Brand New Companies for 2026:
Explore the Agenda
Hear the latest trends in molecular glue development and gain exclusive insights during our packed agenda, interactive roundtables and deep dive workshops.
Partner With Us
Position yourself as a leading solution provider within the molecular glue space to ensure your brand is at the heart of biopharma deals. Â
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees developing molecular glues, and make critical connections during our dedicated networking sessions.